- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06807190
General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
June 26, 2026 updated by: Novo Nordisk A/S
A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan
The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan.
Participants will get Awiqli as prescribed by the study doctor.
The study will last for about 1 year.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
630
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
-
Aichi, Japan, 448-0852
- Enrolling by invitation
- Miyachi Clinic
-
Aichi, Japan, 468-0009
- Enrolling by invitation
- Clinic Tosaki
-
Aichi, Japan, 485-0044
- Enrolling by invitation
- Uenishi Internal Medicine Clinic
-
Aichi, Japan, 470-0126
- Enrolling by invitation
- Fukuoka Naika Clinic_Internal Medicine
-
Aichi, Japan, 494-0001
- Enrolling by invitation
- Ichinomiyanishi Hospital
-
Aichi, Japan, 472-0053
- Enrolling by invitation
- Hattori Clinic Chiryu_Diabetes and Endocrinology
-
Aomori, Japan, 030-0823
- Enrolling by invitation
- Ohisama Clinic_Aomori
-
Aomori, Japan, 038-0011
- Recruiting
- Kakizaki Tonyobyo Naika Clinic
-
Chiba, Japan, 264-0017
- Enrolling by invitation
- Chiba Central Medical Center
-
Chiba, Japan, 292-0822
- Enrolling by invitation
- Kimitsu Chuo Hospital_Diabetology and Endocrinology
-
Chiba, Japan, 270-0034
- Enrolling by invitation
- Shinmatsudo Central General Hospital_Diabetes and Endocrinology
-
Chitose, Hokkaido, Japan, 066-0032
- Not yet recruiting
- Hasegawa Medicine Clinic, Internal medicine
-
Ehime, Japan, 790-0026
- Enrolling by invitation
- Soyokaze CardioVascular Medicine and Diabetes Care
-
Fukuoka, Japan, 815-0071
- Enrolling by invitation
- Clinic Masae Minami
-
Fukuoka, Japan, 818-0024
- Enrolling by invitation
- Ito Naika Clinic_Internal Medicine
-
Fukuoka, Japan, 800-0296
- Enrolling by invitation
- Kyushu Rosai Hospital_Diabetes and Metabolism
-
Fukuoka, Japan, 802-8561
- Enrolling by invitation
- Kitakyushu Municipal Medical Center_Endocrinology and Diabetes
-
Fukuoka, Japan, 805-8508
- Enrolling by invitation
- Steel Memorial Yawata Hospital_Diabetes Internal Medicine
-
Fukuoka, Japan, 812-0053
- Enrolling by invitation
- Okada Naika Clinic
-
Fukuoka, Japan, 802-8555
- Enrolling by invitation
- Kokura Memorial Hospital_Diabetes and Endocrinology
-
Fukuoka, Japan, 830-0023
- Enrolling by invitation
- Tanaka Naika Clinic_Internal Medicine
-
Fukuoka, Japan, 813-0044
- Enrolling by invitation
- Fukuoka Kieikai Hospital_Diabetes and obesity centre
-
Gifu, Japan, 501-1194
- Enrolling by invitation
- Gifu University Hospital_Diabetes and Endocrinology
-
Gifu, Japan, 504-0829
- Enrolling by invitation
- Asano Naika
-
Gunma, Japan, 370-0069
- Enrolling by invitation
- Shimizu Naika
-
Gunma, Japan, 371-8511
- Enrolling by invitation
- Gunma University Hospital_Endocrinology and Diabetes
-
Hiroshima, Japan, 722-0014
- Enrolling by invitation
- Murakami Memorial Hospital_Diabetes Internal Medicine
-
Hokkaido, Japan, 041-0821
- Enrolling by invitation
- Takasawa Diabetes Clinic
-
Hokkaido, Japan, 064-0824
- Enrolling by invitation
- Ito Hiroshi Naika Tonyobyonaika Clinic
-
Hokkaido, Japan, 068-0021
- Enrolling by invitation
- Yoshimura Tonyobyo Clinic
-
Hokkaido, Japan, 073-1105
- Enrolling by invitation
- Kagetsu Clinic
-
Hokkaido, Japan, 004-0053
- Enrolling by invitation
- Kurihara Naika
-
Hyogogoken, Japan, 670-0837
- Enrolling by invitation
- Takabe Diabetes Clinic
-
Hyōgo, Japan, 651-0086
- Enrolling by invitation
- Kagayaki Diabetes and Endocrinology Clinic Sannomiya_Diabetes Internal Medicine
-
Hyōgo, Japan, 651-2135
- Enrolling by invitation
- Matsuda Diabetes Clinic
-
Hyōgo, Japan, 656-0021
- Enrolling by invitation
- Hyogo Prefectural Awaji Medical Center_Diabetes and Endocrinology
-
Ibaraki, Japan, 300-1296
- Enrolling by invitation
- Ushiku Aiwa General Hospital_Diabetes and Metabolism
-
Ibaraki, Japan, 306-0232
- Enrolling by invitation
- Itabashi Diabetes and Dermatology Medical Clinic
-
Ibaraki, Japan, 311-0113
- Enrolling by invitation
- Naka Kinen Clinic_Internal medicine
-
Kagawa, Japan, 769-1695
- Enrolling by invitation
- Mitoyo General Hospital_Internal Medicine
-
Kagoshima-shi, Kagoshima, Japan, 890-0061
- Enrolling by invitation
- Tempozan Clinic of Internal Medicine
-
Kanagawa, Japan, 222-0036
- Enrolling by invitation
- Yokohama Rosai Hospital_Diabetes and Endocrinology
-
Kanagawa, Japan, 236-0033
- Enrolling by invitation
- Kikuchi Naika Clinic_Kanagawa
-
Kanagawa, Japan, 213-8507
- Enrolling by invitation
- Teikyo Univ.HP, Mizonokuchi_Fourth Internal Medicine
-
Kanagawa, Japan, 223-0062
- Enrolling by invitation
- Hiyoshi Clinic_Diabetes Internal Medicine
-
Kanagawa, Japan, 235-0045
- Enrolling by invitation
- H.E.C Science Clinic_Internal Medicine, Diabetes
-
Kanagawa, Japan, 259-1114
- Enrolling by invitation
- Shonanisehara Clinic_Internal Medicine
-
Kanagawa, Japan, 259-1193
- Enrolling by invitation
- Tokai University Hospital_Nephrology, Endocrinology and Metabolism
-
Kisarazu-shi, Chiba, Japan, 292-0038
- Enrolling by invitation
- Hotaruno hakuyukai Medical Corporation of Japan
-
Kumamoto-shi, Kumamoto, Japan, 860-0811
- Enrolling by invitation
- Kumamoto University Hospital, Diabetes, Metabo and Endo
-
Kyoto, Japan, 604-8416
- Enrolling by invitation
- Kamiuchi Naika Clinic
-
Kyoto-shi, Kyoto, Japan, 606-8507
- Enrolling by invitation
- Kyoto University Hospital_Department of Diabetes, Endocr
-
Mie, Japan, 516-0035
- Enrolling by invitation
- MG Clinic
-
Mie, Japan, 514-0125
- Enrolling by invitation
- Mie National Hospital_Internal Medicine
-
Mie, Japan, 516-8512
- Enrolling by invitation
- Japanese Red Cross Ise Hospital_Diabetes and Metabolism
-
Mitaka-shi, Tokyo, Japan, 181-0013
- Enrolling by invitation
- Kanno Naika_Internal Medicine
-
Miyazaki, Japan, 880-0034
- Enrolling by invitation
- Heiwadai Hospital_Diabetes and Internal Medicine
-
Muroran-shi, Hokkaido, Japan, 050-0073
- Enrolling by invitation
- Ato internal medicine clinic, internal medicine
-
Nagano, Japan, 399-4511
- Enrolling by invitation
- Minamiminowa Clinic_Internal Medicine and Endocrinology and Metabolism
-
Nagano, Japan, 385-8558
- Enrolling by invitation
- Asama General Hospital_Diabetology
-
Nagasaki, Japan, 857-8511
- Enrolling by invitation
- Sasebo City General Hospital_Diabetes and Endocrinology
-
Nagasaki, Japan, 859-3242
- Enrolling by invitation
- Kuriya Clinic_Diabetes and Internal Medicine
-
Niigata, Japan, 942-0052
- Enrolling by invitation
- Minagawa Clinic Internal Medicine
-
Niigata, Japan, 950-1101
- Enrolling by invitation
- Niigata Diabetes Clinic_Diabetes and Endocrinology
-
Numakunai, Japan, 024-0061
- Recruiting
- Kitakamiekimae Naika Clinic
-
Okayama, Japan, 701-1192
- Enrolling by invitation
- Okayama Medical Center_Diabetes and Endocrinology
-
Okinawa, Japan, 904-2143
- Enrolling by invitation
- Chibana Clinic
-
Osaka, Japan, 545-0053
- Enrolling by invitation
- Osaka General Hospital of West Japan Railway Company_Diabetes and Metabolism
-
Osaka, Japan, 581-0869
- Enrolling by invitation
- Ogawa Clinic
-
Osaka, Japan, 553-0003
- Enrolling by invitation
- Kansai Electric Power Hospital_Center for Diabetes
-
Osaka, Japan, 558-8558
- Enrolling by invitation
- Osaka General Medical Center_Diabetes and Endocrinology
-
Osaka, Japan, 569-1192
- Enrolling by invitation
- Takatsuki General Hospital_Diabetes and Endocrinology
-
Osaka, Japan, 570-8507
- Enrolling by invitation
- Kansai Medical University Medical Center_Cardiology and Endocrinology and Metabolism
-
Osaka, Japan, 5918025
- Enrolling by invitation
- Japan Organization of Occupational Health and Safety Osaka Rosai Hospital_Diabetes Internal Medicine
-
Osaka, Japan, 591-8006
- Recruiting
- Matsuda Gastroenterology and Diabetes Clinic_Internal Medicine
-
Saga, Japan, 849-4193
- Recruiting
- Imari Arita Kyoritsu Hospital_Internal Medicine
-
Saga, Japan, 846-0012
- Enrolling by invitation
- Saga Chuo Public Hospital_Diabetes Internal Medicine
-
Saitama, Japan, 350-0205
- Enrolling by invitation
- Higashisakado Clinic_Diabetes Internal Medicine
-
Saitama, Japan, 330-8553
- Enrolling by invitation
- Japanese Red Cross Saitama Hospital_Diabetes and Endocrinology
-
Saitama, Japan, 350-0851
- Enrolling by invitation
- Asano Clinic
-
Saitama, Japan, 330-0074
- Enrolling by invitation
- Saitama Medical Center_Diabetes and Endocrinology
-
Sendai-shi, Miyagi, Japan, 983-0824
- Enrolling by invitation
- Matsudakai Tsurugaya Clinic, Internal medicine
-
Shiga, Japan, 526-8580
- Enrolling by invitation
- Nagahama City Hospital_Nephrology and Metabolism
-
Shimane, Japan, 697-0062
- Enrolling by invitation
- Yamane Hospital
-
Shimane, Japan, 694-0041
- Enrolling by invitation
- Yamauchi Naika_Internal Medicine
-
Shizuoka, Japan, 430-0802
- Enrolling by invitation
- Kikuchi Medical Clinic
-
Shizuoka, Japan, 410-2295
- Enrolling by invitation
- Juntendo University Shizuoka Hospital_Diabetes and Endocrinology
-
Tochigi, Japan, 326-0053
- Enrolling by invitation
- Nagasaki Hospital_Internal Medicine
-
Tochigi, Japan, 323-0022
- Enrolling by invitation
- Oyama East Clinic_Internal Medicine
-
Tokyo, Japan, 105-0004
- Enrolling by invitation
- Aoi Clinic_Diabetes and Internal Medicine
-
Tokyo, Japan, 150-0013
- Enrolling by invitation
- Matsuura Clinic
-
Tokyo, Japan, 153-8934
- Enrolling by invitation
- Tokyo Kyosai Hospital_Diabetes and Endocrinology
-
Tokyo, Japan, 158-8531
- Enrolling by invitation
- Kanto Central Hospital of the Mutual Aid Association of Public School Teachers_Diabetes and Endocrinology
-
Tokyo, Japan, 206-0033
- Enrolling by invitation
- Tamacenter Clinic Mirai
-
Tokyo, Japan, 102-0074
- Enrolling by invitation
- Kudanzaka Hospital_Internal Medicine
-
Tokyo, Japan, 105-8471
- Enrolling by invitation
- The Jikei University Hospital Dept of Diabetes, Metabolic
-
Tokyo, Japan, 135-0042
- Enrolling by invitation
- Okamoto Naika Clinic
-
Tokyo, Japan, 153-0051
- Enrolling by invitation
- Mishuku Hospital_Endocrinology and Metabolism
-
Tokyo, Japan, 162-0054
- Enrolling by invitation
- Tokyo Women's Medical University_Diabetes and Metabolism
-
Tokyo, Japan, 162-8655
- Enrolling by invitation
- National Center for Global Health and Medicine_Diabetes and Endocrinology
-
Tokyo, Japan, 178-0063
- Enrolling by invitation
- KAWASAKI internal medicine clinic & Diabetic
-
Tokyo, Japan, 192-0032
- Enrolling by invitation
- Tokai University Hachioji Hospital_Neph.& Endocrinology,Metab.
-
Tottori, Japan, 683-0012
- Recruiting
- Honda Clinic_Internal Medicine
-
Wakayama, Japan, 641-8510
- Enrolling by invitation
- Wakayama Medical Univercity Hospital_Diabetes and Endocrinology
-
Yamagata, Japan, 990-8510
- Not yet recruiting
- Tohoku Central Hospital_Diabetes Internal Medicine
-
Yamagata, Japan, 996-0035
- Enrolling by invitation
- Kouchi Iin
-
Yamaguchi, Japan, 744-0005
- Enrolling by invitation
- Kudamatsu Central Hospital_Internal Medicine
-
Yamato-shi, Kanagawa, Japan, 242-0004
- Enrolling by invitation
- Tsuruma Kaneshiro Diabetes Clinic_Internal medicine
-
Ōita, Japan, 879-7301
- Enrolling by invitation
- Okamoto Clinic for Diabetes and Endocrinology
-
-
Fukushima, Japan
-
Koriyama-shi, Fukushima, Fukushima, Japan, Japan, 963-8851
- Enrolling by invitation
- Seino Internal Medicine Clinic_Internal medicine
-
-
Japan
-
Oita-shi, Oita,, Japan, Japan, 870 0039
- Enrolling by invitation
- Abe Diabetes Clinic_Internal Medicine
-
-
Kumamoto, Japan
-
Kumamoto, Kumamoto, Japan, Japan, 862-0976
- Enrolling by invitation
- Jinnouchi Hospital_Internal Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
The study population comprises patients who are diagnosed with diabetes mellitus and who agree to be treated with Awiqli after consultation with their physician independently from the decision to participate in this study.
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available Awiqli has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
- Male or female with no age limitation.
- Diagnosis of diabetes mellitus. There is no limitation for type of diabetes mellitus and prior treatment for diabetes mellitus.
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Treatment with any investigational drug within 30 days prior to enrolment into the study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- Contraindication described in Japanese package insert.
- Participants showing hypoglycaemic symptoms.
- Participants with a history of hypersensitivity to any ingredients of this drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Awiqli
Participants with diabetes mellitus will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.
|
Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Adverse Reactions (ARs)
Time Frame: From baseline (week 0) to end of study (week 52)
|
Measured as number of events.
|
From baseline (week 0) to end of study (week 52)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Adverse Events (AEs)
Time Frame: From baseline (week 0) to end of study (week 52)
|
Measured as number of events.
|
From baseline (week 0) to end of study (week 52)
|
|
Number of Serious Adverse Events (SAEs)
Time Frame: From baseline (week 0) to end of study (week 52)
|
Measured as number of events.
|
From baseline (week 0) to end of study (week 52)
|
|
Number of Serious Adverse Reactions (SARs)
Time Frame: From baseline (week 0) to end of study (week 52)
|
Measured as number of events.
|
From baseline (week 0) to end of study (week 52)
|
|
Change in Glycosylated Haemoglobin (HbA1c)
Time Frame: From baseline (week 0) to end of study (week 52)
|
Measured as percentage (%) point of HbA1c.
|
From baseline (week 0) to end of study (week 52)
|
|
Change in Fasting Plasma Glucose (FPG)
Time Frame: From baseline (week 0) to end of study (week 52)
|
Measured as milligrams per decilitre (mg/dL).
|
From baseline (week 0) to end of study (week 52)
|
|
Change in Diabetes Therapy-Related Quality Of Life (DTR-QOL)
Time Frame: From baseline (week 0) to end of study (week 52)
|
DTR-QOL is a Japanese questionnaire assessing the influence of diabetes treatment on the individual health related quality of life on 4 domains: "burden on social activities and daily activities", "anxiety and dissatisfaction with treatment", "hypoglycaemia" and "satisfaction with treatment".
DTR-QOL contains 29 questions and the response scale is a 7-point scale (1: strongly agree to 7: strongly disagree).
The score of each item will be reversed so that "7: strongly disagree" represents the highest/desirable QOL.
The total score, after simple addition of the item scores, is converted to 0 to 100 (best-case response is 100; worst case response is 0).
|
From baseline (week 0) to end of study (week 52)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2025
Primary Completion (Estimated)
July 31, 2027
Study Completion (Estimated)
January 31, 2028
Study Registration Dates
First Submitted
January 29, 2025
First Submitted That Met QC Criteria
January 29, 2025
First Posted (Actual)
February 4, 2025
Study Record Updates
Last Update Posted (Actual)
June 29, 2026
Last Update Submitted That Met QC Criteria
June 26, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1436-7680
- U1111-1286-0463 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...RecruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes MellitusIraq, Pakistan
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Abdullah KarsNot yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)Turkey (Türkiye)
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
Clinical Trials on Insulin Icodec
-
Novo Nordisk A/SNot yet recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruiting
-
Novo Nordisk A/SNot yet recruiting
-
Novo Nordisk A/SActive, not recruitingDiabetes Mellitus, Type 1Italy, Germany
-
Gan and Lee Pharmaceuticals, USAProfil Institut für Stoffwechselforschung GmbHRecruiting
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Canada, Taiwan, Argentina, China, Austria, Puerto Rico, France, Czechia, Denmark, Mexico, Brazil
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Germany, South Africa, Bulgaria, Japan, Poland, Portugal, South Korea, Ukraine
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Austria
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Finland, United States, Taiwan, Australia, India, China, Norway, Italy, Japan, Belgium, Mexico, Bulgaria, Croatia, Poland, Romania, Serbia, South Africa, Portugal, South Korea, Puerto Rico, Turkey (Türkiye), Russia
-
Gan & Lee Pharmaceuticals.Recruiting